Calypso Biotech is the third spin-off company from the EPP Fund. The company is developing an anti IL-15 antibody against immune disorders, currently evaluated in celiac disease and eosinophilic esophagitis. Calypso Biotech is based in Geneva, Switzerland and Amsterdam, Netherlands.
Location: Netherlands, North Holland, Amsterdam
Total raised: $55.8M
Investors 2
| Date | Name | Website |
| 21.02.2023 | M Ventures | m-ventures... |
| - | Gilde Heal... | gildehealt... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 09.09.2021 | - | $33.1M | - |
| 21.02.2019 | Series A | $22.69M | Gilde Heal... |
Mentions in press and media 14
| Date | Title | Description |
| 08.01.2024 | Calypso Enters into Agreement to Be Acquired by Novartis | Calypso is a European biotech translating Interleukin-15 biology into medical breakthroughs by developing CALY-002, an anti-IL-15 monoclonal antibody, for an array of autoimmune indications The acquisition of Calypso gives Novartis full ri... |
| 08.01.2024 | Novartis pays $250m upfront to acquire Calypso Biotech | |
| 20.09.2021 | Clinical progression and €8M funding for Calypso Biotech | Calypso Biotech’s lead program, CALY-002, is a best-in-class therapeutic antibody that binds to and neutralizes interleukin-15 (IL-15). IL-15 controls immune pathways critically involved in disease onset and maintenance, as well as tissue d... |
| 09.09.2021 | Calypso Biotech announces first patient with Celiac Disease dosed in anti-Interleukin-15 (IL-15) monoclonal antibody CALY-002 Phase 1b Trial, and extension of Series A to €28M | Calypso Biotech, a leader in the development of Interleukin-15 (IL-15) targeted therapies, announces today completion of dosing of first Celiac Disease patient in the Phase 1 clinical trial of CALY-002, a novel humanized monoclonal antibo... |
| 09.09.2021 | Calypso Biotech Announces First Patient With Celiac Disease Dosed in anti-Interleukin-15 (IL-15) Monoclonal Antibody CALY-002 Phase 1b Trial, and Extension of Series A to €28M | - |
| 26.02.2019 | String of successes for Merck Serono spin-offs | |
| 21.02.2019 | Gilde Healthcare leads EUR 20M Series A financing round of Calypso Biotech | Utrecht, The Netherlands and Boston, US - Calypso Biotech (Amsterdam, The Netherlands), an emerging leader in the development of therapeutic antibodies for autoimmune diseases, announces today the closing of a €20M Series A financing led by... |
| 21.02.2019 | Term Sheet — Thursday, February 21 | LYFT PREDICTIONS Good morning, Term Sheet readers. Paid Content Securing the enterprise without boundaries From ExtraHop Ride-hailing giant Lyft is preparing to list its shares on the Nasdaq near the end of March, according to The Wall Stre... |
| 20.02.2019 | Calypso Biotech BV Secures 20 Million EUR in Series A Financing and Strengthens Team to Develop Anti-IL-15 Therapeutic Antibody for Autoimmune Diseases | - |
| 20.02.2019 | Daily funding roundup - February 20th, 2019 | ThinkGenetic has raised $1.5M; Staytuned raised $2.5M; Senseon raised $6.4M; ParkHub raised $13M ThinkGenetic: ThinkGenetic is a cutting-edge tool empowering patients who want to know about possible genetic causes for their medical issues. ... |
Show more